LET SCIENCE DO THE TALKING
We are a small molecule drug discovery and development biotech that uses a target-centric approach and classical medicinal chemistry to create new medicines
Metastatic melanoma cells
Photo by National Cancer Institute
CURADEV IN THE NEWS
Curadev Announces First Treatment Cycle Completion for the First Patient Dosed in a Phase 1 a/b Clinical Trial of its Allosteric STING Agonist CRD3874-SI in Patients with Advanced Cancer at Memorial Sloan Kettering Cancer Center in New York
Curadev is a clinical stage biotech company, dedicated to discovering and developing novel small molecule therapeutics for the treatment of intractable diseases. Utilizing a target-centric approach, innovative screening schemes and traditional wet-lab chemistry and pharmacology, Curadev has built an impressive portfolio of discovery research programs, resulting in patent-protected drug candidates that modulate next-generation drug targets.
Intuition is the product of persistent practice